Opus Genetics revised its OPGx-BEST1 clinical data presentation, correcting the visual-acuity translation and reporting that 75% of evaluable participants met the FDA-aligned microperimetry measure. The update gives investors corrected participant-level visual-acuity information and higher-resolution microperimetry images while the program advances toward additional 2027 clinical milestones.

Key Highlights

  • The revised presentation adds high-resolution baseline and 3-month microperimetry grids for each participant.
  • Opus Genetics expects further OPGx-BEST1 clinical data and key-trial dosing activity in 2027.
  • The revision corrects an immaterial error in translating logMAR visual acuity into ETDRS letters.

Opus Genetics, Inc. (NASDAQ: IRD) revised its OPGx-BEST1 clinical data presentation after correcting an error in the translation of visual-acuity measurements.

Corrected Visual-Acuity Presentation

Opus Genetics also added high-resolution microperimetry grids covering baseline and 3-month assessments for each participant. Individual loci information is available for three participants through those images. The presentation describes the error as immaterial. It also includes clinical highlights stating that treatment was well tolerated, with no serious adverse events, dose-limiting toxicities or intraocular inflammation.

Disease Population and 2027 Plans

The presentation estimates global BEST1 prevalence at approximately 45,400 patients and U.S. prevalence at 23,600 patients. BEST1-related diseases account for approximately 3.5% of inherited retinal diseases, according to the presentation. Opus Genetics expects additional OPGx-BEST1 clinical data in 2027 and plans to begin key-trial dosing during 2027.